Profund Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.72M | Sell |
51,450
-20,658
| -29% | -$513K | 0.05% | 236 |
|
|
2026
Q1 | $1.51M | Buy |
72,108
+15,484
| +27% | +$349K | 0.06% | 248 |
|
|
2025
Q4 | $1.3M | Buy |
56,624
+24,360
| +76% | +$801K | 0.04% | 288 |
|
|
2025
Q3 | $971K | Buy |
32,264
+16,098
| +100% | +$483K | 0.03% | 339 |
|
|
2025
Q2 | $588K | Sell |
16,166
-1,414
| -8% | -$51K | 0.02% | 422 |
|
|
2025
Q1 | $637K | Sell |
17,580
-1,011
| -5% | -$42.1K | 0.03% | 408 |
|
|
2024
Q4 | $782K | Sell |
18,591
-22
| -0.1% | -$1.09K | 0.03% | 350 |
|
|
2024
Q3 | $1.03M | Sell |
18,613
-3,788
| -17% | -$193K | 0.04% | 316 |
|
|
2024
Q2 | $921K | Sell |
22,401
-5,083
| -18% | -$217K | 0.03% | 322 |
|
|
2024
Q1 | $1.28M | Sell |
27,484
-7,531
| -22% | -$355K | 0.05% | 290 |
|
|
2023
Q4 | $1.67M | Buy |
35,015
+4,954
| +16% | +$192K | 0.07% | 207 |
|
|
2023
Q3 | $1.07M | Buy |
30,061
+1,355
| +5% | +$53.7K | 0.06% | 268 |
|
|
2023
Q2 | $1.32M | Sell |
28,706
-3,195
| -10% | -$148K | 0.07% | 247 |
|
|
2023
Q1 | $1.28M | Buy |
31,901
+24,081
| +308% | +$1.03M | 0.08% | 232 |
|
|
2022
Q4 | $362K | Buy |
7,820
+183
| +2% | +$7.2K | 0.02% | 545 |
|
|
2022
Q3 | $316K | Sell |
7,637
-353
| -4% | -$18.1K | 0.02% | 560 |
|
|
2022
Q2 | $477K | Sell |
7,990
-501
| -6% | -$30.8K | 0.03% | 429 |
|
|
2022
Q1 | $617K | Sell |
8,491
-881
| -9% | -$61.3K | 0.03% | 459 |
|
|
2021
Q4 | $788K | Sell |
9,372
-1,628
| -15% | -$132K | 0.03% | 402 |
|
|
2021
Q3 | $992K | Buy |
11,000
+173
| +2% | +$15.6K | 0.03% | 354 |
|
|
2021
Q2 | $1.03M | Sell |
10,827
-2,201
| -17% | -$229K | 0.03% | 354 |
|
|
2021
Q1 | $1.48M | Sell |
13,028
-980
| -7% | -$133K | 0.06% | 242 |
|
|
2020
Q4 | $1.94M | Buy |
14,008
+2,398
| +21% | +$284K | 0.08% | 198 |
|
|
2020
Q3 | $954K | Sell |
11,610
-1,777
| -13% | -$147K | 0.05% | 287 |
|
|
2020
Q2 | $1.05M | Buy |
13,387
+2,299
| +21% | +$152K | 0.06% | 260 |
|
|
2020
Q1 | $493K | Sell |
11,088
-4,591
| -29% | -$238K | 0.04% | 367 |
|
|
2019
Q4 | $670K | Buy |
15,679
+1,969
| +14% | +$81.2K | 0.03% | 485 |
|
|
2019
Q3 | $587K | Sell |
13,710
-659
| -5% | -$35.8K | 0.03% | 523 |
|
|
2019
Q2 | $912K | Sell |
14,369
-1,024
| -7% | -$65.2K | 0.04% | 396 |
|
|
2019
Q1 | $1.07M | Buy |
15,393
+1,444
| +10% | +$82.5K | 0.05% | 314 |
|
|
2018
Q4 | $607K | Sell |
13,949
-3,401
| -20% | -$186K | 0.04% | 401 |
|
|
2018
Q3 | $1.32M | Buy |
17,350
+1,747
| +11% | +$142K | 0.05% | 302 |
|
|
2018
Q2 | $1.2M | Sell |
15,603
-1,050
| -6% | -$67.8K | 0.05% | 320 |
|
|
2018
Q1 | $849K | Buy |
16,653
+889
| +6% | +$44.8K | 0.03% | 497 |
|
|
2017
Q4 | $731K | Sell |
15,764
-1,689
| -10% | -$82.8K | 0.03% | 607 |
|
|
2017
Q3 | $930K | Buy |
17,453
+1,533
| +10% | +$90.8K | 0.04% | 442 |
|
|
2017
Q2 | $989K | Sell |
15,920
-1,142
| -7% | -$68.8K | 0.04% | 390 |
|
|
2017
Q1 | $1.16M | Sell |
17,062
-1,179
| -6% | -$89.9K | 0.05% | 363 |
|
|
2016
Q4 | $1.28M | Sell |
18,241
-1,744
| -9% | -$124K | 0.06% | 297 |
|
|
2016
Q3 | $1.42M | Sell |
19,985
-121
| -0.6% | -$7.72K | 0.07% | 266 |
|
|
2016
Q2 | $983K | Sell |
20,106
-689
| -3% | -$44.6K | 0.05% | 402 |
|
|
2016
Q1 | $1.32M | Sell |
20,795
-4,896
| -19% | -$320K | 0.07% | 250 |
|
|
2015
Q4 | $2.88M | Buy |
25,691
+315
| +1% | +$31.5K | 0.14% | 113 |
|
|
2015
Q3 | $2.44M | Buy |
+25,376
| New | +$2.91M | 0.14% | 100 |
|
Other funds holding RARE
RI
FCM
Profund Advisors's RARE Position: Q2 2026 in Review
Profund Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 29% in Q2 2026, selling an estimated $513K and leaving 51,450 shares worth $1.72M. The position accounts for 0.05% of the portfolio, ranked #236.
Profund Advisors first reported a position in RARE in Q3 2015 and has held it in 44 quarters since. The position peaked at $2.88M in Q4 2015. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.
- Profund Advisors held 51,450 shares of Ultragenyx Pharmaceutical worth $1.72M as of Q2 2026.
- Profund Advisors sold 20,658 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $513K.
- Ultragenyx Pharmaceutical made up 0.05% of Profund Advisors's portfolio in Q2 2026, its #236 holding.
- Profund Advisors first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and has held it in 44 quarters since.
- Profund Advisors's Ultragenyx Pharmaceutical position peaked at $2.88M in Q4 2015.
- 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.
Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.